tradingkey.logo
tradingkey.logo
Buscar

Bausch + Lomb Corp

BLCO
Añadir a la lista de seguimiento
16.540USD
-0.090-0.54%
Cierre 06/30, 16:00ETCotizaciones retrasadas 15 min
5.86BCap. mercado
PérdidaP/E TTM

Más Datos de Bausch + Lomb Corp Compañía

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Información de Bausch + Lomb Corp

Símbolo de cotizaciónBLCO
Nombre de la empresaBausch + Lomb Corp
Fecha de salida a bolsaMay 06, 2022
Director ejecutivoSaunders (Brenton L)
Número de empleados13500
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 06
Dirección520 Applewood Crescent
CiudadVAUGHAN
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísCanada
Código postalL4K 4B4
Teléfono19082552864
Sitio Webhttps://ir.bausch.com/
Símbolo de cotizaciónBLCO
Fecha de salida a bolsaMay 06, 2022
Director ejecutivoSaunders (Brenton L)

Ejecutivos de Bausch + Lomb Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
87.02K
-1.16%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
72.80K
-18.77%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
57.52K
+62.90%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
27.66K
+57.27%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mr. John A. Paulson ,
Mr. John A. Paulson ,
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
87.02K
-1.16%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
72.80K
-18.77%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
57.52K
+62.90%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
27.66K
+57.27%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Bausch + Lomb Corp?

Los cinco principales accionistas de Bausch + Lomb Corp son: Mr. Luc Bonnefoy

¿Cuántas instituciones poseen acciones de Bausch + Lomb Corp (BLCO)?

A fecha de 2026Q1, 249 instituciones poseen acciones de Bausch + Lomb Corp, con un valor de mercado combinado de aproximadamente 40.30M, lo que representa el 11.30% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -25007155.00.

¿Cuál es la mayor fuente de ganancias de Bausch + Lomb Corp?

El 2026Q1, el segmento empresarial Devices generó la ganancia más alta para Bausch + Lomb Corp, ascendiendo a 1.92B y representando el 37.68% de la ganancia total.
KeyAI